Ocular Therapeutix officer executed sell‑to‑cover sale of 9,653 shares
Rhea-AI Filing Summary
Officer sale under pre-set plan: An officer of Ocular Therapeutix, Inc. (OCUL) reported the sale of 9,653 shares of common stock under a durable automatic sale instruction intended to satisfy tax withholding on RSU vesting. The transactions were effected on 10/02/2025 as non‑discretionary sales tied to the reporting person’s sell‑to‑cover election for restricted stock units that vested on 10/01/2025.
The filing reports a weighted average sale price of $11.03 (trade prices ranged between $10.99 and $11.0697) and shows the reporting person retained beneficial ownership of 194,440 shares after the transactions. The form was signed by an attorney‑in‑fact and discloses the sale was pursuant to a plan adopted on 04/09/2024.
Positive
- Transaction executed under a pre‑arranged durable instruction, reducing insider timing concerns
- Sale explicitly for tax withholding on RSU vesting, not a discretionary cash‑out
- Reporting person retains 194,440 shares after the sale, indicating continued ownership
- Weighted average price disclosed with offered breakdown for audit transparency
Negative
- Sale reduces insider holdings by 9,653 shares, a measurable but limited dilution of that insider stake
Insights
Officer sold shares via a pre‑arranged plan to meet tax obligations on vested RSUs.
The transaction shows a routine sell‑to‑cover execution under a Rule 10b5‑1 style durable instruction adopted on 04/09/2024, which typically reduces insider timing risk because trades are pre‑scheduled and non‑discretionary. The sale of 9,653 shares at a weighted average of $11.03 was explicitly for tax withholding on RSUs vested 10/01/2025.
Key dependencies include the continued use of the automatic sale instruction and future RSU vesting schedules; investors can monitor subsequent Form 4 filings for additional pre‑arranged sales or discretionary trades within the next 30–90 days.
Sale size is modest relative to retained holdings, indicating no major de‑risking.
After the reported sale the reporting person still beneficially owns 194,440 shares, so the disposition represented a small portion of total holdings and specifically addressed tax withholding rather than liquidity or diversification. The weighted average sale price range ($10.99–$11.0697) is shown for transparency and the filer offers to provide a price-by-price breakdown if requested.
Watch for the number and timing of future sell‑to‑cover transactions tied to RSU vesting dates such as the recent 10/01/2025 vesting; changes in the automatic plan terms would appear on amended filings.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 9,653 | $11.03 | $106K |
Footnotes (1)
- Represents shares of common stock of Ocular Therapeutix, Inc. (the "Corporation") sold, pursuant to a durable automatic sale instruction adopted by the reporting person on April 9, 2024, effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations in connection with the vesting of restricted stock units on October 1, 2025. The sales do not represent a discretionary trade by the reporting person. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.99 to $11.0697, inclusive. The reporting person undertakes to provide to the Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.
